Drug intelligence / Profile preview

trastuzumab-DOTA-GA

Development stage
Preclinical
Lead developer
Oncodesign Services
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

trastuzumab-DOTA-GA is an antibody-radio conjugate (ARC) precursor consisting of the HER2-targeted monoclonal antibody trastuzumab conjugated to the chelating agent DOTA-GA (DOTAGA). Developed by Debiopharm and Oncodesign Services using Debiopharm's proprietary AbYlink™ regioselective conjugation technology, the payload is site-specifically attached to the Fc region of the antibody, preserving its antigen-binding affinity. The DOTA-GA chelator enables subsequent radiolabeling with various isotopes, such as Indium-111, Gallium-68, or Lutetium-177, for applications in molecular imaging (SPECT/PET) and targeted radionuclide therapy. It is currently in preclinical development for the detection and treatment of HER2-positive cancers, including gastric cancer.

Other names
111In-DOTAGA-trastuzumab111In-trastuzumab-DOTA-GA111In-trastuzumab-DOTAGAtrastuzumab-DOTAGA
02

Identity

Drug type
Antibody-Based Therapeutics
Modality
Antibody-Based TherapeuticsAntibody-Radionuclide Conjugates
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
gastric cancer and precursor lesionsPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

07

Competitive landscape

Drugs on the same target
273
Drugs in the lead indication
681

Lead indication: gastric cancer and precursor lesions

Most advanced in the lead indication

  1. aminocaproic acidApproved
  2. capecitabineApproved
  3. dacomitinibApproved
  4. doxorubicinApproved
  5. lazertinibApproved

Beyond the preview

Go deeper on trastuzumab-DOTA-GA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on trastuzumab-DOTA-GA.

Work on trastuzumab-DOTA-GA? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call